Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019

BACKGROUND: Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa, which are more common in patients with lower respiratory tract infections (LRTIs) and in patients in intensive care units (ICUs), pose difficult treatment challenges and may require new therapeutic options. Two β-lact...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle H, DePestel, Daryl D, DeRyke, C Andrew, Kazmierczak, Krystyna M, Young, Katherine, Motyl, Mary R, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297703/
https://www.ncbi.nlm.nih.gov/pubmed/34307727
http://dx.doi.org/10.1093/ofid/ofab320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297703/
https://www.ncbi.nlm.nih.gov/pubmed/34307727
http://dx.doi.org/10.1093/ofid/ofab320

Ejemplares similares